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Alterations in cardiac function were observed in antidepressants treated patients and published in several 
clinical reports. These detected changes could be either a consequence of the treatment or of depression 
itself, which has already been proved to be a risk factor in heart diseases. In order to determine a possible 
influence of chronic treatment with norepinephrinergic reuptake inhibitor, maprotiline, on the heart, we 
investigated gene expression of cardiac β-adrenoceptors both in controls and in animals with signs of 
depression. The rats were divided into two groups, unstressed controls and those exposed to chronic 
unpredictable mild stress (CUMS). The groups were further divided into two subgroups, one receiving 
daily intraperitoneal injections of vehicle (sterile water) and another one maprotiline (10 mg/kg) for 
four weeks. Tissue samples were collected after the last application. Gene expression of cardiac β1- and  
β2-adrenoceptor was determined using Real-time RT-PCR analysis. Our results show that in control 
animals expression of both adrenoreceptors was decreased in the right atria after 4 weeks of maprotiline 
application. Contrary, the same treatment led to a significant increase in expression of cardiac β1-
adrenoceptor in the stressed rats, with no change in the characteristics of β2-adrenoceptor. Our findings 
might reflect the that molecular mechanisms are underlying factors involved in the development of 
cardiovascular diseases linked with antidepressant treatment.
Uniterms: Antidepressants. Depression/treatment. Cardiovascular diseases/associated with the use of 
antidepressants. ß-adrenoceptors/gene expression.
Vários relatórios clínicos observaram alterações de funcionamento cardíaco de pacientes depressivos 
que foram tratados com os antidepressivos. As alterações detectadas podem ser consequência do 
tratamento ou, por outro lado, da depressão que, como se tem provado, é um fator de risco no caso de 
doenças cardíacas. De modo a determinar a possível influência de tratamento crônico com o inibidor da 
recaptação de norepinefrina, maprotilina, no coração, foi investigada a expressão do gene aos receptores 
β-adrenérgicos cardíacos dos animais em grupos de controle e em grupos com sinais de depressão. Os 
ratos foram divididos em grupos de controle não estressados e os grupos de ratos submetidos ao estresse 
crônico moderado imprevisível (CUMS). Os grupos foram, ainda, divididos em dois subgrupos, que, 
durante quatro semanas, diariamente receberam injeções intraperitoneais de placebo (água estéril) ou de 
maprotilina (10 mg/kg). As amostras de tecido foram coletadas após a última aplicação. A expressão do 
gene aos receptores adrenérgicos β1 e β2 foi determinada utilizando a análise PCR quantitativa em tempo 
real (RT-PCR). Os nossos resultados demonstram a diminuição de expressão dos ambos os receptores 
adrenérgicos no átrio direito dos animais do grupo de controle depois de quatro semanas de aplicação 
de maprotilina. Em contraste, o mesmo tratamento conduziu ao aumento significativo na expressão do 
receptor β1-adrenérgico no coração dos ratos estressados, sem qualquer alteração nas características 
do receptor β2-adrenérgico. Estes resultados podem refletir os mecanismos moleculares envolvidos no 
desenvolvimento de doenças cardiovasculares associadas ao tratamento com os antidepressivos.
Unitermos: Antidepressivos. Depressão/tratamento. Doenças cardiovasculares/associação ao uso de 
antidepressivos. Receptores ß-adrenérgicos cardíacos/expressão do gene.
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INTRODUCTION
Depression is associated with the autonomic nervous 
system dysfunction that could have a negative impact on 
cardiovascular function (Carney et al., 2005). Several 
studies have demonstrated an exaggerated norepinephrine 
response in major depression (Lake et al., 1982; Veith et 
al., 1994; Yehuda et al., 1998; Mausbach et al., 2005). 
Chronic exposure to elevated levels of catecholamines, 
released from sympathetic nerve terminals and the ad-
renal gland, may cause pathologic changes, resulting in 
alterations in cardiac structure and function (Brum et al., 
2002, Lohse et al., 2003). Activation of the closely related 
β1- and β2-adrenergic receptors (β1-AR and β2-AR) by re-
leased catecholamines is the primary trigger of molecular 
changes in the heart. These two subtypes are expressed in 
cardiac tissue at a ratio of 70:30, and their activation lead 
to an increase in contractile force and heart rate (Wallu-
kat, 2002). The ratio of β1-AR to β2-AR subtypes depends 
on the type of animals and it is modified in pathological 
conditions (Brodd, Michel, 1999). Both receptors are 
highly homologous and activate the G protein stimulatory 
for adenylyl cyclase (Gs),yet they have distinguishable 
biological effects (Xiang, Kobilka, 2003). Thus, the β1-
AR plays the dominant role in stimulating heart rate and 
strength of myocyte contraction, whereas β2-AR produces 
only modest chronotropic effects. Furthermore, chronic 
stimulation of β1-AR produces myocyte hypertrophy and 
apoptosis, whereas β2-AR signaling promotes cell survival 
(Xiao et al., 2004).
Stress is a key etiological factor in anxiety and ma-
jor depressive disorders (Caspi et al., 2003). The chronic 
unpredictable mild stress (CUMS) procedure is an animal 
model that mimics the role of chronic stress in precipitat-
ing depression and induces various long-term physical, 
behavioural, neurochemical and neuroendocrine altera-
tions that resemble those observed in depressed patients, 
which are reversed only by chronic antidepressants treat-
ments (Wilner et al., 1992; Mineur et al., 2006; Yalcin et 
al., 2007). Maprotiline is a antidepressant with an atypical 
tetracyclic structure, which function is to prevent reuptake 
by blocking norepinephrine transporter. It is commonly 
used in elderly patients suffering from depression as long-
term medication (Ahles et al., 1984). In the past, there have 
been only several clinical reports on the rise in heart rate 
(Hewer et al., 1995) and proarrhythmia (Lentini et al., 
2001; Zuchner, 2002) linked to maprotiline. 
This raises a question of a possible influence of 
maprotiline on β-adrenergic receptors gene expression 
in the heart of these animals. Applying TaqMan RT-PCR 
we have estimated the influence of long-term treatment 
with norepinephrinergic reuptake inhibitor, maprotiline, 
on gene expression of β1 and β2 adrenoreceptors, in the 
right and left atria as well as in the ventricle of unstressed 
controls and rats exposed to CUMS for 4 weeks.
MATHERIAL AND METHODS
Animals and study design
Adult Wistar rat males weighing 280-320 g at the 
onset of experiments and maintained in a temperature-
-controlled room (21±1.0 oC) and 12 h/12 h light/dark 
cycle, were used. Care was taken to minimise the pain and 
discomfort of the animals in accordance with the Guide 
for Care and Use of Laboratory Animals of the National 
Institute of Health, Bethesda, MD, U.S.A. Research 
investigations were approved by Ethical Committee of 
the “Vinca” Institute, Belgrade (Application No. 02/11). 
The rats were randomly divided into control (unstressed) 
and group subjected to CUMS according to the method 
by Grippo et al. (2006). These two groups were further 
divided into two subgroups each, and the animals were 
receiving daily injections of vehicle (sterile water) or 
maprotiline (10 mg/kg) by i.p. route. Exposure to CUMS 
and the vehicle, i.e. drug administration started on the 
same day and were continued for 4 weeks. Maprotiline 
(Sigma-Aldrich Chemie, Germany) solutions in sterile 
water, sonicated for approximately 10 min were prepared 
ex tempore. Upon completion of 4 weeks, the animals 
exposed to CUMS and the corresponding controls were 
decapitated, the right and left cardiac atria and ventricles 
rapidly dissected, frozen in liquid nitrogen and stored at 
−70 oC until analysed.
RNA isolation and cDNA synthesis
Total RNAs were isolated using TRIZOL reagent 
(Invitrogen, CA, U.S.A.). Reverse transcription was per-
formed using Ready-To-Go You-Prime First- Strand Bead 
(AP, Biotech) and pd (N)6 primer according to manufac-
turer’s protocol.
Real-time RT-PCR
TaqMan PCR assays were carried out using Assay-
on-Demand Gene Expression Products (Applied Biosys-
tems, USA) for β1–AR (Rn 00824536_s1) and β2–AR (Rn 
00560650_s1). The reactions were performed in a 25 µL 
reaction mixture containing 1x TaqMan Universal Master 
Mix with AmpErase UNG, 1x Assay Mix (Applied Bio-
systems) and cDNA template (10 ng of RNA converted to 
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cDNA). PCR reactions were performed in the ABI Prism 
7000 Sequence Detection System at 50 ◦C for 2 min, 95 
◦C for 10 min, followed by 40 cycles at 95 oC for 15 s and 
60 oC for 1 min. A reference, endogenous control, was 
included in each analysis to correct the differences in the 
inter-assay amplification efficiency and all transcripts were 
normalised to cyclophyline A (ID:Rn 00690933) expres-
sion. Quantification was done using the 2-ΔΔCt method 
according to Livak and Schmittgen (2001).
Statistical analysis
The results are reported as means ± S.E.M. Sig-
nificance of the differences between the groups in gene 
expression levels of the examined β-AR were estimated 
by Two-way ANOVA test, followed by the Tukey post 
hoc test. Statistical significance was accepted at p < 0.05.
RESULTS
In our present study, we investigated the alterations 
in relative gene expression of β1- and β2-AR in the right 
and left atria and ventricles after chronic maprotiline 
application in rats exposed to CUMS for 4 weeks in 
comparison with unstressed controls. Results indicate 
that stress procedure induced a considerable effect 
(F (1, 20) = 17.87, p<0.001) on β1-AR gene expression in 
the left atria. Chronic stress increased β1-AR mRNA 
levels by 75% (p <0.01) in the left atria. On the other 
hand, antidepressant treatment affected β1-AR gene 
expression (F (1, 20) = 45.21, p<0.001) in the right atria. 
In addition, maprotiline effect on the unstressed animals 
was quite different from that on the stressed ones. Thus, 
this antidepressant led to an increase in β1-AR mRNA 
levels by 224% (p<0.001) in the right atria of CUMS 
rats, but decreased it by 47% (p<0.001) in controls. 
Analysis of data also displayed a significant interaction 
(F (1, 20) = 9.56, p<0.01) between effects of chronic stress 
and antidepressant treatment on β1-AR mRNA levels 
in the left ventricle. In animals subjected to CUMS 
for 4 weeks and parallelly treated with maprotilin, 
β1-AR mRNA levels were increased by 76% (p<0.01) in 
the left ventricle (Fig. 1).
Two-way ANOVA test pointed to a significant dif-
ference in β2-AR mRNA levels between unstressed and 
chronically stressed groups both in left atria (F(1,20) = 8.01, 
p<0.05) and in the left ventricle (F(1, 20) = 43.52, p<0.001). 
CUMS procedure increased β2-AR mRNA levels in both 
left atria (by 34 %, p<0.05) and left ventricles (by 40 %, 
p<0.01). Maprotiline affected gene expression of β2-AR 
(F(1, 20) = 5.71, p<0.05) in right atria. Antidepressant treat-
ment decreased β2-AR levels by 21% (p<0.05) in controls, 
but had no significant effect in stressed rats (Fig. 2). 
DISCUSSION
Antidepressant prescriptions are often associated 
with an increased risk of heart disease (Rosenberg et al., 
2010). Tata et al. (2005) reported that this risk is more 
likely associated to factors relating to depression itself than 
to specific adverse drug effects. Therefore, we examined 
whether the effect of maprotiline treatment on gene ex-
pression of β1 and β2-adrenoceptor in the heart of animals 
with depressive symptoms, which were induced by the 4 
weeks exposure to CUMS, differed from that in unstressed 
rats. In control animals expression of both adrenoreceptors 
was decreased in right atria after four weeks of maprotiline 
application. Down-regulation of the β-adrenergic receptors 
appears to be a common effect of most tricyclic antidepres-
FIGURE 1 - The effects of chronic maprotiline treatment on 
β1– adrenoceptors mRNA levels in left and right cardiac atrium 
and ventricle of unstressed and CUMS rats. The values are 
means ± S.E.M. of 7 rats. Statistical significance: ## p< 0.01; 
### p< 0.001 CUMS vs. control (Tukey-test); **p< 0.01; ***p< 
0.001 maprotiline vs. vehicle (Tukey-test). The final result 
was expressed as fold change relative to the calibrator and 
normalized to cyclophyline A.
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sants (Duman et al., 1997; Deupree et al., 2007). This may 
be related to adaptive processes regarded as a secondary 
effect to the increased concentration of norepinephrine in 
the synaptic cleft. Similarly, prolonged agonist exposure 
decreases both β1-AR binding activity and β1-AR mRNA 
levels (Dunigan et al., 2002). Port et al.(1992) identifed 
a 35 kDa β-AR mRNA-binding protein (β-ARB protein) 
which is involved in agonist-induced destabilization of β2-
AR mRNA. They have shown that the amount of β-ARB 
protein correlates inversely with the decrease in β2-AR 
mRNA during the treatment with agonists in hamster 
heart cells. Antidepressants might also affect β-adrenergic 
receptors transcription that is independent of the inhibition 
of norepinephrine uptake. An intact Sp1 site is required 
for the full activity of the β1-AR promoter in heart cells. 
The conservation of this binding site across mammalian 
β1-AR genes suggests that this element is crucial for the 
β1-AR gene expression regulation (Bahouth et al., 2002). 
It has been observed that chronic desipramine produced a 
significant reduction in Sp1-binding activity (Frechilla et 
al., 1998). In our experiments, as a result of exposure to 
CUMS, a significant increase in β1- and β2-adrenoceptor 
mRNA levels was recorded in left atria whereas β2-ARs 
mRNA levels were increase only in left ventricles. Ac-
cording to Ueyama and colleagues (2003) activation of 
β-ARs is the primary trigger of emotional stress-induced 
molecular changes in the heart. Glucocorticoids are known 
to affect expression of these receptors through GRE se-
quences in promotor region (Malbon, Hadcock, 1988). In 
these animals, as previously shown, plasma corticosterone 
levels were elevated (Dronjak et al., 2007). Similarly, 
Misliveček et al. (2003) noticed that after hydrocortisone 
treatment density of both β1-AR and β2-AR was increased. 
In contrast to control group of animals, maprotiline treat-
ment led to a significant increase in the expression of β1-
AR but remained without effect on β2-AR expression in 
stressed rats. Chronic antidepressant treatment, which en-
hances norepinephrine synaptic transmission, was shown 
to increase phosphorylation of CREB and CRE-mediated 
gene expression in several brain regions (Thome et al., 
2000; Abdel-Razaq et al., 2007). Tseng and co-workers 
(1998) demonstrated that cAMP mediates the induction of 
β1-AR gene expression by interacting with CRE within the 
promoter region. It has been also observed that glucocorti-
coids, which are present during chronic stress, interacting 
with transcription factor CREB, can prevent downregu-
lation of β2-AR number and mRNA expression (Mak et 
al., 1995; Adcock et al., 1996). According to Dangel and 
co-workers (1996), glucocorticoids also induce changes in 
the β2-AR RNA stability by reducing the amount of β-ARB 
protein. In addition, antidepressants could also regulate 
mRNA stability. The studies conducted by Headley and co-
workers (2004) demonstrated that stimulation of mitogen-
activated protein kinases-MAPKs (JNK, p38) resulted in 
marked stabilization of β-AR mRNA. Budziszewska et al. 
(2010) observed that chronic treatment with antidepres-
sant drugs attenuated the stress-induced decreased levels 
of MAPKs in the brain of rats subjected to prenatal stress, 
but had no effect on its concentration in control animals. 
Longer half-life may explain the higher levels of β1-AR 
mRNA in stressed treated animals, in comparison to 
placebo group. The results of the mentioned authors can 
explain the different gene expression of these receptors in 
normal and stressed conditions. Norepinephrine-promoted 
destabilization and stress-induced transcription seem to be 
underlying factors for the interplay of the two opposing 
pathways controlling receptor mRNA levels. Further ex-
periments on transcriptional activation and mRNA stabil-
ity will be required to unravel the complexity of stress- and 
antidepressant-dependent regulation of beta-adrenoceptor 
gene expression. In chronically stressed individuals, 
treated with maprotiline, the increased expression of this 
FIGURE 2 - The effects of chronic maprotiline treatment on β2– 
adrenoceptors mRNA levels in left and right cardiac atrium and 
ventricle of unstressed and CUMS rats. The values are means 
± S.E.M.of 7 rats. Statistical significance: # p<0.05; ## p<0.01 
CUMS vs. control (Tukey-test); *p< 0.05 maprotiline vs. vehicle 
(Tukey-test). The final result was expressed as fold change 
relative to the calibrator and normalized to cyclophyline A.
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receptor might be a prerequisite in the development of 
cardiovascular disease given that it initiates irreversible 
damage to cardiac tissue. 
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